Author

Mark W. Zimmerman

Dana-Farber Cancer InstituteORCID 0000-0003-2489-3889Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Brian J. AbrahamiD· 3 shared Adam David DurbiniD· 2 shared Alfred Thomas LookiD· 2 shared Alla Berezovskaya· 2 shared Kimberly StegmaieriD· 2 shared Alexander LaVeck· 1 shared Amélie VrommaniD· 1 shared Andrew Lee HongiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Brian J. AbrahamORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 3, 2026

Synergistic targeting of EP300/CBP and EYA co-activators collapses the rhabdomyosarcoma core regulatory circuit

Annika L. Gustafson, Stephanie Nance, Berkley E. Gryder…·Adam David Durbin

The paper identifies a core regulatory circuit in rhabdomyosarcoma and shows that targeting two co-activators synergistically inhibits tumor growth.

DOI 10.64898/2026.09.02.748955

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJul 1, 2025

KAT6A/B inhibition synergizes with retinoic acid and enhances the efficacy of GD2-targeted immunotherapy in neuroblastoma

Nina Weichert‐Leahey, Alla Berezovskaya, Mark W. Zimmerman…·Alfred Thomas Look

This study shows that inhibiting KAT6A/B with PF-9363 enhances retinoid efficacy and improves GD2-targeted immunotherapy in neuroblastoma.

2 citations

humanbulk RNA-seq

𝕏 PostBluesky

ImmunologybioRxivPreprintJun 12, 2025

Multitargeted Reduction of Inflammation and Atherosclerosis in Tet2-deficient CHIP via XPO1 Inhibition and Atf3 restoration

Nicole Prutsch, Amélie Vromman, Brittaney A. Leeper…·Alfred Thomas Look

3 citations

𝕏 PostBluesky